UPB
Upstream Bio, Inc. Common StockUPB
UPB
About: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
11% more funds holding
Funds holding: 70 [Q4 2024] → 78 (+8) [Q1 2025]
5.97% more ownership
Funds ownership: 78.5% [Q4 2024] → 84.47% (+5.97%) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
62% less capital invested
Capital invested by funds: $690M [Q4 2024] → $261M (-$429M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for UPB.
Financial journalist opinion
Based on 4 articles about UPB published over the past 30 days
Neutral
GlobeNewsWire
4 hours ago
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand.
Neutral
GlobeNewsWire
1 week ago
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025.
Neutral
GlobeNewsWire
1 week ago
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 9:20 a.m.
Neutral
GlobeNewsWire
3 weeks ago
Upstream Bio Appoints Stacy Price as Chief Technology Officer
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer.
Neutral
GlobeNewsWire
1 month ago
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a summary of recent business highlights.
Positive
Seeking Alpha
1 month ago
Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent
Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Verekitug's less frequent dosing and good safety profile offer potential advantages, but its success hinges on upcoming Phase 2 data readouts.
Positive
Benzinga
2 months ago
3 Dividend Giants To Buy As Tariffs Hit Stocks
This year's tariff storms have hit tech stocks, semiconductor stocks and even metal and mining stocks. Now, they're starting to hit dividend stocks, too.
Neutral
GlobeNewsWire
3 months ago
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
Neutral
GlobeNewsWire
3 months ago
Upstream Bio to Present at Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MA Tuesday, March 4, 2025, 11:50 a.m.
Neutral
Seeking Alpha
5 months ago
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation
Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027.
Charts implemented using Lightweight Charts™